Neuropace Projects Up to $100 Million Revenue in 2026 Outlook

Reuters01-13

Neuropace Projects Up to $100 Million Revenue in 2026 Outlook

NeuroPace Inc. has released its preliminary unaudited financial results for the fourth quarter and full year 2025, along with its initial outlook for 2026. The company expects total revenue for 2025 to be approximately $100 million, representing a 25% increase over 2024. Fourth quarter 2025 revenue is projected to be about $26.6 million, up 24% from the same period in 2024. RNS revenue for 2025 is anticipated to reach $81.7 million, a 25% year-over-year increase. Looking ahead to 2026, NeuroPace forecasts total revenue between $98 million and $100 million, reflecting 20% to 22% growth in core RNS revenue compared to preliminary 2025 results, excluding any contribution from idiopathic generalized epilepsy $(IGE)$. The company expects first quarter 2026 revenue to be in the range of $21 million to $22 million. IGE is expected to contribute following potential approval in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113401077) on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603689125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603689125","market":"fut","top_or_hot":-1,"title":"Neuropace Projects Up to $100 Million Revenue in 2026 Outlook","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neuropace Projects Up to $100 Million Revenue in 2026 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NPCE\">NeuroPace Inc.</a> has released its preliminary unaudited financial results for the fourth quarter and full year 2025, along with its initial outlook for 2026. The company expects total revenue for 2025 to be approximately $100 million, representing a 25% increase over 2024. Fourth quarter 2025 revenue is projected to be about $26.6 million, up 24% from the same period in 2024. RNS revenue for 2025 is anticipated to reach $81.7 million, a 25% year-over-year increase. Looking ahead to 2026, NeuroPace forecasts total revenue between $98 million and $100 million, reflecting 20% to 22% growth in core RNS revenue compared to preliminary 2025 results, excluding any contribution from idiopathic generalized epilepsy <a href=\"https://laohu8.com/S/IGE\">$(IGE)$</a>. The company expects first quarter 2026 revenue to be in the range of $21 million to $22 million. IGE is expected to contribute following potential approval in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113401077) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuropace Projects Up to $100 Million Revenue in 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuropace Projects Up to $100 Million Revenue in 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neuropace Projects Up to $100 Million Revenue in 2026 Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NPCE\">NeuroPace Inc.</a> has released its preliminary unaudited financial results for the fourth quarter and full year 2025, along with its initial outlook for 2026. The company expects total revenue for 2025 to be approximately $100 million, representing a 25% increase over 2024. Fourth quarter 2025 revenue is projected to be about $26.6 million, up 24% from the same period in 2024. RNS revenue for 2025 is anticipated to reach $81.7 million, a 25% year-over-year increase. Looking ahead to 2026, NeuroPace forecasts total revenue between $98 million and $100 million, reflecting 20% to 22% growth in core RNS revenue compared to preliminary 2025 results, excluding any contribution from idiopathic generalized epilepsy <a href=\"https://laohu8.com/S/IGE\">$(IGE)$</a>. The company expects first quarter 2026 revenue to be in the range of $21 million to $22 million. IGE is expected to contribute following potential approval in the second half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113401077) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NPCE","symbol_name":"NeuroPace Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL5PF4Rq:1","article_id":"2603689125","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603689125","pubTimestamp":1768307470,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeuroPace Inc. has released its preliminary unaudited financial results for the fourth quarter and full year 2025, along with its initial outlook for 2026. The company expects total revenue for 2025 to be approximately $100 million, representing a 25% increase over 2024. Fourth quarter 2025 revenue is projected to be about $26.6 million, up 24% from the same period in 2024. RNS revenue for 2025 is anticipated to reach $81.7 million, a 25% year-over-year increase. Looking ahead to 2026, NeuroPace forecasts total revenue between $98 million and $100 million, reflecting 20% to 22% growth in core RNS revenue compared to preliminary 2025 results, excluding any contribution from idiopathic generalized epilepsy . The company expects first quarter 2026 revenue to be in the range of $21 million to $22 million. IGE is expected to contribute following potential approval in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NPCE":"NeuroPace Inc.","BK4539":"次新股","BK4082":"医疗保健设备"},"translate_title":"Neuropace预计2026年收入将达到1亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NPCE":0.9},"content_text":"Neuropace Projects Up to $100 Million Revenue in 2026 Outlook\n    \n\nNeuroPace Inc. has released its preliminary unaudited financial results for the fourth quarter and full year 2025, along with its initial outlook for 2026. The company expects total revenue for 2025 to be approximately $100 million, representing a 25% increase over 2024. Fourth quarter 2025 revenue is projected to be about $26.6 million, up 24% from the same period in 2024. RNS revenue for 2025 is anticipated to reach $81.7 million, a 25% year-over-year increase. Looking ahead to 2026, NeuroPace forecasts total revenue between $98 million and $100 million, reflecting 20% to 22% growth in core RNS revenue compared to preliminary 2025 results, excluding any contribution from idiopathic generalized epilepsy $(IGE)$. The company expects first quarter 2026 revenue to be in the range of $21 million to $22 million. IGE is expected to contribute following potential approval in the second half of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113401077) on January 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603689125","isCrawlerRequest":true}